186 related articles for article (PubMed ID: 22068660)
1. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
Singh R; Zhang Y; Pastan I; Kreitman RJ
Clin Cancer Res; 2012 Jan; 18(1):152-60. PubMed ID: 22068660
[TBL] [Abstract][Full Text] [Related]
2. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
[TBL] [Abstract][Full Text] [Related]
3. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
[TBL] [Abstract][Full Text] [Related]
5. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
6. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
7. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
8. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
[TBL] [Abstract][Full Text] [Related]
11. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Gold DV; Modrak DE; Schutsky K; Cardillo TM
Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
[TBL] [Abstract][Full Text] [Related]
13. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
14. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
15. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Cardillo TM; Blumenthal R; Ying Z; Gold DV
Int J Cancer; 2002 Jan; 97(3):386-92. PubMed ID: 11774294
[TBL] [Abstract][Full Text] [Related]
16. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
17. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
18. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
Beck AW; Luster TA; Miller AF; Holloway SE; Conner CR; Barnett CC; Thorpe PE; Fleming JB; Brekken RA
Int J Cancer; 2006 May; 118(10):2639-43. PubMed ID: 16353142
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]